Alzchem gives presentation at Long Covid Congress - great interest
![[Translate to Englisch:]](/fileadmin/_processed_/8/9/csm_221121_news_creapure_kreatin_konferenz_615a38aef3.jpg)
More than 2500 participants in presence and online, physicians, universities, and patient advocacy groups, attended the first-ever Long Covid Congress, which was broadcasted worldwide. Alzchem was the only company permitted to give a presentation. Initial studies suggest that creatine could contribute to alleviating symptoms of long covid. Creatine is an essential component of cellular energy metabolism, the functioning of which is in turn a prerequisite for important bodily functions. Several studies have shown a correlation between low creatine levels and expression of Long Covid symptoms. Alzchem has subsequently begun to investigate whether creatine supplementation as part of broader therapies can help alleviate Long Covid symptoms. Although final evidence for this assumption is still pending, the interim results are quite encouraging. Alzchem's ideas were received and discussed with great interest. Further studies are planned.
Even three years after the beginning of the pandemic, the late and long-term effects are hardly treatable. Official figures estimate that 17 million people are affected in Europe and 3 million in Germany. The disease is very complex in its severity and expression, making identification and treatment very difficult. Affected persons are often unable to work for months and even years and are massively restricted in their quality of life. Young adults in particular are often affected by the severe cases, which, according to Thuringia's Minister President Bodo Ramlow at the congress, is also increasingly becoming a social problem.
In order to share research results and experiences, several physicians and universities have joined forces in the Long Covid medical association and have now also organized this first specialist congress on the subject of Long Covid. Over two days, information on the latest research and therapies was presented and discussed. The congress was supported by the German Federal Minister of Health, Dr. Lauterbach, and the Prime Minister of Thuringia, Mr. Ramelow, both of whom also attended the congress.
Contact
Robert Alber
About Alzchem
Alzchem is a globally active specialty chemicals company that is predominantly among the market leaders in its fields of activity. Alzchem benefits in particular from the three very different global developments of climate change, population growth and longer life expectancy. In order to achieve the resulting social goals, Alzchem products can offer attractive solutions with a wide range of different applications.
The company sees interesting growth prospects for itself especially in the areas of human and animal nutrition and agriculture. As a result of population growth, it is necessary to achieve efficient food production. Pharmaceutical raw materials and our creatine products can contribute to healthy aging as life expectancy increases. Alzchem is facing up to the goal of sustainability arising from climate change in the field of renewable energies and across the entire company. The fields of fine chemicals and metallurgy offer just as great a perspective.
The broad product range of Alzchem Group AG includes dietary supplements, precursors for corona tests and pharmaceutical raw materials. These products are our company’s response to global trends and developments. Alzchem is ideally positioned in this regard and sees itself as well equipped for an environmentally oriented future and global developments.
The company employs around 1,630 people at four production sites in Germany and one plant in Sweden, as well as two sales companies in the USA and China. In 2020, Alzchem generated consolidated sales of around EUR 379 million and EBITDA of around EUR 53.8 million.